<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04164186</url>
  </required_header>
  <id_info>
    <org_study_id>ALSP</org_study_id>
    <nct_id>NCT04164186</nct_id>
  </id_info>
  <brief_title>Fully Automated Pipeline for the Detection and Segmentation of Non-Small Cell Lung Cancer (NSCLC) on CT Images</brief_title>
  <official_title>Fully Automated Pipeline for the Detection and Segmentation of Non-Small Cell Lung Cancer (NSCLC) on CT Images: Quantitative and Qualitative Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Liege</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital RWTH Aachen University, Aachen, Germany.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang street, Dalian 116001, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Accurate segmentation of lung tumor is essential for treatment planning, as well as for&#xD;
      monitoring response to therapy. It is well-known that segmentation of the lung tumour by&#xD;
      different radiologists gives different results (inter-observer variance). Moreover, if the&#xD;
      same radiologist is asked to repeat the segmentation after several weeks, these two&#xD;
      segmentations are not identical (intra-observer variance). In this study we aim to develop an&#xD;
      automated pipeline that can produce swift, accurate and reproducible lung tumor&#xD;
      segmentations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we aim to develop and test an automated deep learning detection and&#xD;
      segmentation software for non-small cell lung cancer (NSCLC) that can automatically detect&#xD;
      and segment tumors on CT scans and thus reduce the human variation. We will assess the level&#xD;
      of agreement between a group of radiologists, performing manual versus semi-automatic tumour&#xD;
      segmentation. To do so, we will provide radiologists with two sets of CT scans. The first set&#xD;
      will be segmented manually; the second one will be segmented using the automated software&#xD;
      program.&#xD;
&#xD;
      Subsequently, we will use the inter- and intra-observer variance from the clinical study in a&#xD;
      simulation or modeling study. We also compare the time needed and the consistency in&#xD;
      segmentations by the software to medical doctors performance.&#xD;
&#xD;
      Reliability and Agreement study:&#xD;
&#xD;
      Primary tumours of 25 lung cancer patients will be delineated by 6 segmentation experts.&#xD;
&#xD;
        1. Assess agreement between automatic segmentation and radiologists' segmentation The&#xD;
           primary tumours of 25 patients will be manually segmented by the radiologists and&#xD;
           automatically by the the tool. The time needed to perform this task and the&#xD;
           reproducibility of the segmentation will be recorded. The degree of overlap between the&#xD;
           ROs and the automatic contour will be assessed pairwise using the Dice coefficient.&#xD;
&#xD;
        2. Delination of tumours by the experts, assisted by the software tool For another 25&#xD;
           patients, the experts will be provided with an automatic delineation, performed by the&#xD;
           tool. They have the possibility to adjust and validate it. The time needed will be&#xD;
           recorded. The difference between the mean overlap fraction in the first situation&#xD;
           (manual delineation of experts) and the second situation (delineation of experts+&#xD;
           software tool) will be assessed, using a multi-observer Dice coefficient.&#xD;
&#xD;
        3. Assessment of intra-observer variance The experts will repeat the segmentation of the&#xD;
           lung tumours after 2 weeks. They will repeat the manual segmentation (n=25) and the&#xD;
           semi-automatic segmentation (n=25). This will make it possible to assess the&#xD;
           intra-observer variance in both situations.&#xD;
&#xD;
        4. Qualitative assessment of the experts' preferences using an in-house developed&#xD;
           visualization toolbox.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">March 10, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Actual">November 7, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of NSCLC on CT scans</measure>
    <time_frame>November, 2019</time_frame>
    <description>Automatic detection of NSCLC tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Segmentation of NSCLC scans</measure>
    <time_frame>November, 2019</time_frame>
    <description>Automatic segmentation of NSCLC tumors</description>
  </primary_outcome>
  <enrollment type="Actual">1043</enrollment>
  <condition>Detection</condition>
  <condition>Segmentation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Automatic detection and segmentation of NSCLC tumors</intervention_name>
    <description>an automated deep learning detection and segmentation software for non-small cell lung cancer (NSCLC) that can automatically detect and segment tumors on CT scans and thus reduce the human variation.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        CT scans of 1043 patients diagnosed with NSCLC at one of the 8 centers (Netherlands, USA,&#xD;
        China, Belgium) were collected retrospectively. All patients had a biopsy to confirm the&#xD;
        diagnosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Availability of CT scans&#xD;
&#xD;
          -  Availability of definite diagnosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of segmentations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Currently, there is no plan to make it public</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>NSCLC Radiomics Interobserver</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://wiki.cancerimagingarchive.net/display/Public/NSCLC-Radiomics-Interobserver1</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>NSCLC Radiomics</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://wiki.cancerimagingarchive.net/display/Public/NSCLC-Radiomics</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>NSCLC Radiogenomics</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://wiki.cancerimagingarchive.net/display/Public/NSCLC+Radiogenomics</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

